Rational design of therapeutics targeting the BCL-2 family: Are some cancer cells primed for death but waiting for a final push?

Advances in Experimental Medicine and Biology

Volumn 615, Issue , 2008, Pages 159-175

  Moore, Victoria Del Gaizo ^a   Letai, Anthony ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; BCL 2; BH3; Peptide; Therapeutics

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; BH3 PROTEIN; BIM PROTEIN; DACARBAZINE; DEXAMETHASONE; FAS LIGAND; GOSSYPOL DERIVATIVE; GX 01; OBLIMERSEN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

BACKACHE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DEHYDRATION; DNA DAMAGE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; LARGE CELL LYMPHOMA; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; UPREGULATION; WEIGHT REDUCTION; ANIMAL; APOPTOSIS; DRUG ANTAGONISM; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 43249107590     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4020-6554-5_8     Document Type: Review

References (106)

1. Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E., and Croce, C. M. The t(14;18) (1985). Chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390-1393.
2. Cleary, M. L. and Sklar, J. (1985). Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82, 7439-7443.
3. Bakhshi, A., Jensen, J. P., Goldman, P., Wright, J. J., McBride, O. W., Epstein, A. L., and Korsmeyer, S. J. (1985). Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41, 899-906.
4. Packham, G. (1998). Mutation of BCL-2 family proteins in cancer. Apoptosis 3, 75-82.
5. McDonnell, T. J. and Korsmeyer, S. J. (1991). Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349, 254-256.
6. Strasser, A., Harris, A. W., Bath, M. L., and Cory, S. (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333.
7. Scorrano, L., Oakes, S. A., Opferman, J. T., Cheng, E. H., Sorcinelli, M. D., Pozzan, T., and Korsmeyer, S. J. (2003). BAX and BAK regulation of endoplasmic reticulum Ca2 +: a control point for apoptosis. Science 300, 135-139.
8. Bassik, M. C., Scorrano, L., Oakes, S. A., Pozzan, T., and Korsmeyer, S. J. (2004). Phosphorylation of BCL-2 regulates ER Ca2 + homeostasis and apoptosis. EMBO J 23, 1207-1216.
9. Kamer, I., Sarig, R., Zaltsman, Y., Niv, H., Oberkovitz, G., Regev, L., Haimovich, G., Lerenthal, Y., Marcellus, R. C., and Gross, A. (2005). Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122, 593-603.
10. Zinkel, S. S., Hurov, K. E., Ong, C., Abtahi, F. M., Gross, A., and Korsmeyer, S. J. (2005). A role for proapoptotic BID in the DNA-damage response. Cell 122, 579-591.
11. Danial, N. N., Gramm, C. F., Scorrano, L., Zhang, C. Y., Krauss, S., Ranger, A. M., Datta, S. R., Greenberg, M. E., Licklider, L. J., Lowell, B. B., Gygi, S. P., and Korsmeyer, S. J. (2003). BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424, 952-956.
12. Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R., and Thompson, C. B. (2001). BH3- only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15, 1481-1486.
13. Cheng, E. H., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., and Korsmeyer, S. J. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8, 705-711.
14. Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730.
15. Puthalakath, H. and Strasser, A. (2002). Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9, 505-512.
16. Danial, N. N. and Korsmeyer, S. J. (2004). Cell death: critical control points. Cell 116, 205-219.
17. Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., and Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192.
18. Lindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., Chen, Y., Wei, M., Eng, V. M., Adelman, D. M., Simon, M. C., Ma, A., Golden, J. A., Evan, G., Korsmeyer, S. J., MacGregor, G. R., and Thompson, C. B. (2000). The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 6, 1389-1399.
19. Wei, M. C., Lindsten, T., Mootha, V. K., Weiler, S., Gross, A., Ashiya, M., Thompson, C. B., and Korsmeyer, S. J. (2000). tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14, 2060-2071.
20. Suzuki, M., Youle, R. J., and Tjandra, N. (2000). Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103, 645-654.
21. Griffiths, G. J., Dubrez, L., Morgan, C. P., Jones, N. A., Whitehouse, J., Corfe, B. M., Dive, C., and Hickman, J. A. (1999). Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144, 903-914.
22. Desagher, S., Osen-Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, S., Maundrell, K., Antonsson, B., and Martinou, J. C. (1999). Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144, 891-901.
23. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42.
24. Li, L. Y., Luo, X., and Wang, X. (2001). Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412, 95-99.
25. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-489.
26. Wang, J. L., Zhang, Z. J., Choksi, S., Shan, S., Lu, Z., Croce, C. M., Alnemri, E. S., Korngold, R., and Huang, Z. (2000). Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 60, 1498-1502.
27. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397, 441-446.
28. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53.
29. Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev 15, 2922-2933.
30. Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., and Green, D. R. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014.
31. Moll, U. M., Wolff, S., Speidel, D., and Deppert, W. (2005). Transcription-independent proapoptotic functions of p53. Curr Opin Cell Biol 17, 631-636.
32. Murphy, M. E., Leu, J. I., and George, D. L. (2004). p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 3, 836-839.
33. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E., and George, D. L. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6, 443-450.
34. Cheng, E. H., Levine, B., Boise, L. H., Thompson, C. B., and Hardwick, J. M. (1996). Baxindependent inhibition of apoptosis by Bcl-XL. Nature 379, 554-556.
35. Certo, M., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A., and Letai, A. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9(5), 351-365.
36. Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., and Newmeyer, D. D. (2005). BH3 Domains of BH3-only proteins differentially regulate Baxmediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17, 525-535.
37. Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., and Huang, D. C. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17, 393-403.
38. Li, H., Zhu, H., Xu, C. J., and Yuan, J. (1998). Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501.
39. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (1999). BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13, 1899-1911.
40. Kitada, S., Pedersen, I. M., Schimmer, A. D., and Reed, J. C. (2002). Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21, 3459-3474.
41. Wang, S., Yang, D., and Lippman, M. E. (2003). Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 30, 133-142.
42. Mounier, N., Briere, J., Gisselbrecht, C., Emile, J. F., Lederlin, P., Sebban, C., Berger, F., Bosly, A., Morel, P., Tilly, H., Bouabdallah, R., Reyes, F., Gaulard, P., and Coiffier, B. (2003). Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101, 4279-4284.
43. Gascoyne, R. D., Adomat, S. A., Krajewski, S., Krajewska, M., Horsman, D. E., Tolcher, A. W., O'Reilly, S. E., Hoskins, P., Coldman, A. J., Reed, J. C., and Connors, J. M. (1997). Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90, 244-251.
44. Hill, M. E., MacLennan, K. A., Cunningham, D. C., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., Selby, P., and Linch, D. C. (1996). Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 88, 1046-1051.
45. Joensuu, H., Pylkkanen, L., and Toikkanen, S. (1994). Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145, 1191-1198.
46. Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C., and Harris, A. L. (1994). bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69, 135-139.
47. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M., and Campbell, M. L. (1992). Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52, 6940-6944.
48. Sinicrope, F. A., Hart, J., Michelassi, F., and Lee, J. J. (1995). Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1, 1103-1110.
49. Buolamwini, J. K. (1999). Novel anticancer drug discovery. Curr Opin Chem Biol 3, 500-509.
50. Caligaris-Cappio, F. and Hamblin, T. J. (1999). B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17, 399-408.
51. Schimmer, A. D., Munk-Pedersen, I., Minden, M. D., and Reed, J. C. (2003). Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 4, 211-218.
52. Jewell, A. P. (2002). Role of apoptosis in the pathogenesis of B-cell chronic lymphocytic leukaemia. Br J Biomed Sci 59, 235-238.
53. Schena, M., Gottardi, D., Ghia, P., Larsson, L. G., Carlsson, M., Nilsson, K., and Caligaris- Cappio, F. (1993). The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk Lymphoma 11, 173-179.
54. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E., and Reed, J. (1993). C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82, 1820-1828.
55. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., and Croce, C. M. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99, 15524-15529.
56. Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
57. Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., and Johnson, J. M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769-773.
58. Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. I., Fabbri, M., Iuliano, R., Palumbo, T., Pichiorri, F., Roldo, C., Garzon, R., Sevignani, C., Rassenti, L., Alder, H., Volinia, S., Liu, C. G., Kipps, T. J., Negrini, M., and Croce, C. M. A (2005). MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353, 1793-1801.
59. Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., Rassenti, L., Alder, H., Volinia, S., Liu, C. G., Kipps, T. J., Negrini, M., and Croce, C. M. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102, 13944-13949.
60. Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., Ray, T. S., Koval, M. A., Last, K. W., Norton, A., Lister, T. A., Mesirov, J., Neuberg, D. S., Lander, E. S., Aster, J. C., and Golub, T. R. (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8, 68-74.
61. Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M. J., Harousseau, J. L., Bataille, R., and Amiot, M. (2002). Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100, 194-199.
62. Berrieman, H. K., Smith, L., O'Kane, S. L., Campbell, A., Lind, M. J., and Cawkwell, L. (2005). The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes. Cancer 103, 1415-1419.
63. Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., Lee, C., Wagner, S. N., Li, C., Golub, T. R., Rimm, D. L., Meyerson, M. L., Fisher, D. E., and Sellers, W. R. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
64. McGill, G. G., Horstmann, M., Widlund, H. R., Du, J., Motyckova, G., Nishimura, E. K., Lin, Y. L., Ramaswamy, S., Avery, W., Ding, H. F., Jordan, S. A., Jackson, I. J., Korsmeyer, S. J., Golub, T. R., and Fisher, D. E. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718.
65. Thallinger, C., Wolschek, M. F., Wacheck, V., Maierhofer, H., Gunsberg, P., Polterauer, P., Pehamberger, H., Monia, B. P., Selzer, E., Wolff, K., and Jansen, B. (2003). Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120, 1081-1086.
66. Henderson, S., Huen, D., Rowe, M., Dawson, C., Johnson, G., and Rickinson, A. (1993). Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 90, 8479-8483.
67. Cheng, E. H., Nicholas, J., Bellows, D. S., Hayward, G. S., Guo, H. G., Reitz, M. S., and Hardwick, J. M. (1997). A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA 94, 690-694.
68. Gauthier, E. R., Piche, L., Lemieux, G., and Lemieux, R. (1996). Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res 56, 1451-1456.
69. Miguel-Garcia, A., Orero, T., Matutes, E., Carbonell, F., Miguel-Sosa, A., Linares, M., Tarin, F., Herrera, M., Garcia-Talavera, J., and Carbonell-Ramon, F. (1998). bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica 83, 298-304.
70. Jourdan, M., Veyrune, J. L., Vos, J. D., Redal, N., Couderc, G., and Klein, B. (2003). A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22, 2950-2959.
71. Zhang, B., Gojo, I., and Fenton, R. G. (2002). Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99, 1885-1893.
72. Green, D. R. and Evan, G. I. (2002). A matter of life and death. Cancer Cell 1, 19-30.
73. Hahn, W. C. and Weinberg, R. A. (2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer 2, 331-341.
74. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S., Nimmer, P. M., O'Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen, W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt, M. D., Zhang, H., Fesik, S. W., and Rosenberg, S. H. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
75. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. (1998). bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4, 232-234.
76. O'Brien, S. M., Cunningham, C. C., Golenkov, A. K., Turkina, A. G., Novick, S. C., and Rai, K. R. (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23, 7697-7702.
77. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., and Cotter, F. E. (2000). Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18, 1812-1823.
78. Konopleva, M., Tari, A. M., Estrov, Z., Harris, D., Xie, Z., Zhao, S., Lopez-Berestein, G., and Andreeff, M. (2000). Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95, 3929-3938.
79. Levin, V. A. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23, 682-684.
80. Begley, D. J. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 48, 136-146.
81. Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., and Korsmeyer, S. J. (2004). Activation of apoptosis in vivo by a hydrocarbon- stapled BH3 helix. Science 305, 1466-1470.
82. Service, R. F. (2000). Biochemistry. Protein arrays step out of DNA's shadow. Science 289, 1673.
83. Schwarze, S. R., Ho, A., Vocero-Akbani, A., and Dowdy, S. F. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572.
84. Levchenko, T. S., Rammohan, R., Volodina, N., and Torchilin, V. P. (2003). Tat peptidemediated intracellular delivery of liposomes. Methods Enzymol 372, 339-349.
85. Lewin, M., Carlesso, N., Tung, C. H., Tang, X. W., Cory, D., Scadden, D. T., and Weissleder, R. (2000). Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18, 410-414.
86. Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G., and Prochiantz, A. (1996). Cell internalization of the third helix of the Antennapedia homeodomain is receptorindependent. J Biol Chem 271, 18188-18193.
87. Mi, Z., Mai, J., Lu, X., and Robbins, P. D. (2000). Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol Ther 2, 339-347.
88. Mann, D. A. and Frankel, A. D. (1991). Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 10, 1733-1739.
89. Schimmer, A. D., Hedley, D. W., Chow, S., Pham, N. A., Chakrabartty, A., Bouchard, D., Mak, T. W., Trus, M. R., and Minden, M. D. (2001). The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ 8, 725-733.
90. Goldsmith, K. C., Liu, X., Dam, V., Morgan, B. T., Shabbout, M., Cnaan, A., Letai, A., Korsmeyer, S. J., and Hogarty, M. D. (2006). BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma. Oncogene 25, 4525-33.
91. Tomita, M., Hayashi, M., and Awazu, S. (1995). Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells. J Pharmacol Exp Ther 272, 739-743.
92. Vieira, H. L., Haouzi, D., Hamel, C. E., Jacotot, E., Belzacq, A., Brenner, C., and Kroemer, G. (2000). Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ 7, 1146-1154.
93. Westerhoff, H. V., Juretic, D., Hendler, R. W., and Zasloff, M. (1989). Magainins and the disruption of membrane-linked free-energy transduction. Proc Natl Acad Sci USA 86, 6597-6601.
94. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. (1999). Anticancer activity of targeted pro-apoptotic peptides. Nat Med 5, 1032-1038.
95. Matsuzaki, K. (2001). Why and how are peptide-lipid interactions utilized for self defence? Biochem Soc Trans 29, 598-601.
96. Chin, J. W. and Schepartz, A. (2001). Design and evolution of a miniature Bcl-2 binding protein. Angew. Chem Int Ed 40, 3806-3809.
97. Yang, B., Liu, D., and Huang, Z. (2004). Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. Bioorg Med Chem Lett 14, 1403-1406.
98. Wang, J. L., Liu, D., Zhang, Z. J., Shan, S., Han, X., Srinivasula, S. M., Croce, C. M., Alnemri, E. S., and Huang, Z. (2000). Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97, 7124-7129.
99. Enyedy, I. J., Ling, Y., Nacro, K., Tomita, Y., Wu, X., Cao, Y., Guo, R., Li, B., Zhu, X., Huang, Y., Long, Y. Q., Roller, P. P., Yang, D., and Wang, S. (2001). Discovery of smallmolecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 44, 4313-4324.
100. Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., and Yuan, J. (2001). Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3, 173-182.
101. Nakashima, T., Miura, M., and Hara, M. (2000). Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60, 1229-1235.
102. Tzung, S. P., Kim, K. M., Basanez, G., Giedt, C. D., Simon, J., Zimmerberg, J., Zhang, K. Y., and Hockenbery, D. M. (2001). Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3, 183-191.
103. Leone, M., Zhai, D., Sareth, S., Kitada, S., Reed, J. C., and Pellecchia, M. (2003). Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 63, 8118-8121.
104. Kitada, S., Leone, M., Sareth, S., Zhai, D., Reed, J. C., and Pellecchia, M. (2003). Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46, 4259-4264.
105. Becattini, B., Kitada, S., Leone, M., Monosov, E., Chandler, S., Zhai, D., Kipps, T. J., Reed, J. C., and Pellecchia, M. (2004). Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 11, 389-395.
106. Shore, G. C. and Viallet, J. (2005). Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology (Am Soc Hematol Educ Program) 226-230.